EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF ‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study

Daisuke Kotani, Eisuke Inoue, Tadamichi Denda, Chiaki Inagaki, Tomomi Kashiwada, Yoshiaki Mihara, Akinori Sugaya, Yusuke Suwa, Takashi Ohta, Hidekazu Kuramochi, Kotoe Oshima, Satoshi Yuki und 6 weitere

The Oncologist · 09.03.2026 · 31 (4)

DOI: 10.1093/oncolo/oyag068 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Oncologist, online erschienen am 27.02.2026. Verfasst von Daisuke Kotani und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan. Hauptthemen laut MEDLINE: Cetuximab, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ono Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triplet therapy (encorafenib, cetuximab, and binimetinib) is recommended in Japan for BRAF V600E mutated metastatic colorectal cancer (mCRC) patients with poor prognostic factors (PFs) based on subgroup analyses of the BEACON CRC trial. We, therefore, conducted a nationwide prospective observational study to evaluate the real-world effectiveness of triplet versus doublet therapy (encorafenib plus cetuximab). Patients and Methods The BEETS trial (UMIN000045530) enrolled BRAF-mutated mCRC patients who received triplet or doublet as second- or third-line treatment. The primary endpoint was overall survival (OS). Exploratory analyses using inverse probability weighting (IPW) based on propensity scores were performed to adjust for poor PFs (ECOG performance status ≥1, ≥3 metastatic sites, elevated C-reactive protein, or unresected primary tumor).

Results

In 203 enrolled patients, 195 patients were evaluable. Median age was 67 years; 52% were male. Dose intensity for encorafenib and cetuximab was comparable between the triplet and doublet cohorts. In the overall cohort, median OS and progression-free survival (PFS) were 12.9 and 4.9 months, respectively. After IPW adjustment, median OS was 14.0 months in the triplet cohort and 12.9 months in the doublet cohort (HR 0.87, 95%CI 0.57-1.33). Median PFS was 5.3 versus 4.2 months (HR 0.75, 95%CI 0.48-1.19). Among patients with at least one poor PF, both OS and PFS numerically favored the triplet regimen.

Conclusions

In real-world clinical practice, triplet and doublet therapies showed comparable survival outcomes, consistent with the BEACON trial. Triplet therapy may provide potential clinical benefit in patients with poor PFs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CetuximabColorectal NeoplasmsProto-Oncogene Proteins B-rafAntineoplastic Combined Chemotherapy ProtocolsHumansCarbamatesSulfonamidesMaleFemaleBenzimidazolesAgedMutationMiddle AgedProspective StudiesNeoplasm Metastasis

Stichwörter der Autor:innen

BRAF mutatedbinimetinibcetuximabencorafenibmetastatic colorectal cancer

Substanzen

encorafenibCetuximabCarbamatesSulfonamidesProto-Oncogene Proteins B-rafbinimetinibBRAF protein, humanBenzimidazoles

Autor:innen und Institutionen

  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
  • Showa Medical University Research Administration Center, Showa Medical University, Tokyo, 142-8555, Japan.
  • Division of Gastroenterology, Chiba Cancer Center, Chiba, 260-8717, Japan.
  • Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, 590-0197, Japan.
  • Department of Medical Oncology, Saga-Ken Medical Center Koseikan, Saga, 840-8571, Japan.
  • Division of Medical Oncology, Showa Medical University Fujigaoka Hospital, Yokohama, 227-8501, Japan.

ORCID-Profile: Kei Muro, Yu Sunakawa

Förderung

  • Ono Pharmaceutical Co., Ltd

Zitieren

APA

Kotani, D., Inoue, E., Denda, T., Inagaki, C., Kashiwada, T., Mihara, Y., Sugaya, A., Suwa, Y., Ohta, T., Kuramochi, H., Oshima, K., Yuki, S., Shiozawa, M., Tsuji, A., Muro, K., Ichikawa, W., Fujii, M., & Sunakawa, Y. (2026). Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF ‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study. The Oncologist, 31(4). https://doi.org/10.1093/oncolo/oyag068

Vancouver

Kotani D, Inoue E, Denda T, Inagaki C, Kashiwada T, Mihara Y, et al. Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF ‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study. The Oncologist. 2026;31(4). doi:10.1093/oncolo/oyag068

BibTeX
@article{Kotani2026,
  author = {Kotani, Daisuke and Inoue, Eisuke and Denda, Tadamichi and Inagaki, Chiaki and Kashiwada, Tomomi and Mihara, Yoshiaki and Sugaya, Akinori and Suwa, Yusuke and Ohta, Takashi and Kuramochi, Hidekazu and Oshima, Kotoe and Yuki, Satoshi and Shiozawa, Manabu and Tsuji, Akihito and Muro, Kei and Ichikawa, Wataru and Fujii, Masashi and Sunakawa, Yu},
  title = {Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF ‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {4},
  doi = {10.1093/oncolo/oyag068}
}
Kostenlos starten →